Trials / Completed
CompletedNCT00412854
Study to Assess Safety & Immunogenicity of GSK Biologicals' DTPa/Hib Vaccine vs Separate Administration of DTPa and Hib.
Phase IIIb, Multicentre Study to Assess Safety & Immunogenicity of GSK Biologicals' Combined DTPa/Hib (Infanrix/Hib) Vaccine vs Separate Administration of DTPa (Infanrix) & Hib (Hiberix) Vaccines in Healthy Infants 3,4,&5 Months of Age as Compared With the Separate Administration of DTPa and Hib Vaccines at Different Injection Sites.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 660 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 90 Days – 120 Days
- Healthy volunteers
- Accepted
Summary
This study will compare GSK Biologicals' DTPa/Hib vaccine to separately administered DTPa and Hib vaccines in Chinese infants 3, 4 \& 5 months of age, in terms of safety and immunogenicity.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Infanrix™/Hib | |
| BIOLOGICAL | Infanrix | |
| BIOLOGICAL | Hiberix |
Timeline
- Start date
- 2007-01-03
- Primary completion
- 2007-06-01
- Completion
- 2007-06-25
- First posted
- 2006-12-19
- Last updated
- 2018-06-06
- Results posted
- 2017-02-10
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT00412854. Inclusion in this directory is not an endorsement.